Next Article in Journal
Candida antarctica Lipase B Immobilized onto Chitin Conjugated with POSS® Compounds: Useful Tool for Rapeseed Oil Conversion
Next Article in Special Issue
Essential Roles of Natural Products and Gaseous Mediators on Neuronal Cell Death or Survival
Previous Article in Journal
Alterations in Serum Polyunsaturated Fatty Acids and Eicosanoids in Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Previous Article in Special Issue
The Role of Cyclo(His-Pro) in Neurodegeneration

Protein Kinases and Parkinson’s Disease

Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Division of Neurotoxicology, National Center for Toxicological Research/US Food and Drug Administration, Jefferson, AR 72079, USA
Geriatric Research Education and Clinical Center, Central Arkansas Veterans Healthcare System, Little Rock, AR 72205, USA
Author to whom correspondence should be addressed.
Academic Editor: Katalin Prokai-Tatrai
Int. J. Mol. Sci. 2016, 17(9), 1585;
Received: 30 May 2016 / Revised: 9 August 2016 / Accepted: 1 September 2016 / Published: 20 September 2016
(This article belongs to the Special Issue Neuroprotective Strategies 2016)
Currently, the lack of new drug candidates for the treatment of major neurological disorders such as Parkinson’s disease has intensified the search for drugs that can be repurposed or repositioned for such treatment. Typically, the search focuses on drugs that have been approved and are used clinically for other indications. Kinase inhibitors represent a family of popular molecules for the treatment and prevention of various cancers, and have emerged as strong candidates for such repurposing because numerous serine/threonine and tyrosine kinases have been implicated in the pathobiology of Parkinson’s disease. This review focuses on various kinase-dependent pathways associated with the expression of Parkinson’s disease pathology, and evaluates how inhibitors of these pathways might play a major role as effective therapeutic molecules. View Full-Text
Keywords: Parkinson’s disease; dopamine; tyrosine kinase; serine/threonine kinase; kinase inhibitors Parkinson’s disease; dopamine; tyrosine kinase; serine/threonine kinase; kinase inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Mehdi, S.J.; Rosas-Hernandez, H.; Cuevas, E.; Lantz, S.M.; Barger, S.W.; Sarkar, S.; Paule, M.G.; Ali, S.F.; Imam, S.Z. Protein Kinases and Parkinson’s Disease. Int. J. Mol. Sci. 2016, 17, 1585.

AMA Style

Mehdi SJ, Rosas-Hernandez H, Cuevas E, Lantz SM, Barger SW, Sarkar S, Paule MG, Ali SF, Imam SZ. Protein Kinases and Parkinson’s Disease. International Journal of Molecular Sciences. 2016; 17(9):1585.

Chicago/Turabian Style

Mehdi, Syed J., Hector Rosas-Hernandez, Elvis Cuevas, Susan M. Lantz, Steven W. Barger, Sumit Sarkar, Merle G. Paule, Syed F. Ali, and Syed Z. Imam 2016. "Protein Kinases and Parkinson’s Disease" International Journal of Molecular Sciences 17, no. 9: 1585.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop